Plain-English translation of NCT06125327 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called Sufenidone () can help slow or improve idiopathic pulmonary fibrosis, a serious lung disease where scar tissue builds up in your lungs over time. You would take the medication or a placebo (a pill with no active ingredient) twice a day for one year. Researchers will compare how people on the medication do compared to those on placebo to see if this treatment helps.
Idiopathic pulmonary fibrosis is a progressive disease with limited treatment options, and many patients continue to decline despite current therapies. This trial aims to find out whether this medication might offer a new way to help people with this condition breathe better and live longer.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly over 56 weeks (just over one year). For the first 52 weeks, you would take either the medication or a placebo tablet twice a day—once in the morning and once in the evening. Neither you nor your doctors would know which group you are in (that is called "blinded"). During your visits, the research team will monitor your lung function with breathing tests, check your overall health, and watch for any side effects. After the 52-week treatment period ends, you would have 4 additional weeks of safety monitoring.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Guangzhou JOYO Pharma Co., Ltd
Enrollment target
~210 participants
Started
June 2023
Primary completion
December 2026
Age range
40 Years – 80 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
zuojun xu
Guangzhou JOYO Pharma Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.